Phase II Trial of Akt Inhibitor MK2206 in Patients With Advanced Breast Cancer Who Have Tumors With a PIK3CA Mutation, or an AKT Mutation, and/or PTEN Loss/PTEN Mutation
Phase of Trial: Phase II
Latest Information Update: 18 Jan 2017
At a glance
- Drugs MK 2206 (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 21 Nov 2016 Status changed from active, no longer recruiting to completed.
- 19 Mar 2014 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.